Search results for "Lipide"

showing 10 items of 532 documents

EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study

2021

Abstract Aims To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement. Methods and results An 18 country, cross-sectional, observational study of patients prescribed LLT for primary or secondary prevention in primary or secondary care across Europe. Between June 2017 and November 2018, data were collected at a single visit, including LLT in the preceding 12 months and most recent LDL-C. Primary outcome was the achievement of risk-based 2016 European Society of Cardiology (ESC)/European Atherosclerosis…

medicine.medical_specialtyRegistryStatinEpidemiologymedicine.drug_class030204 cardiovascular system & hematologyGuidelinesSecondary care03 medical and health sciences0302 clinical medicineEzetimibeRisk FactorsInternal medicinemedicineHumans030212 general & internal medicinePCSK9 InhibitorsDyslipidemiasSecondary preventionPrimary Health Carebusiness.industryAnticholesteremic AgentsStatinsCholesterol LDLGuidelineLipidsConfidence intervalCross-Sectional StudiesTreatment OutcomeCholesterolCardiovascular DiseasesObservational studyHydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9Cardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugDA VINCI study
researchProduct

Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Network

2020

ABSTRACTBackgroundSpain has been one of the countries most affected by the COVID-19 pandemic.ObjectiveTo create a registry of patients with COVID-19 hospitalized in Spain in order to improve our knowledge of the clinical, diagnostic, therapeutic, and prognostic aspects of this disease.MethodsA multicentre retrospective cohort study, including consecutive patients hospitalized with confirmed COVID-19 throughout Spain. Epidemiological and clinical data, additional tests at admission and at seven days, treatments administered, and progress at 30 days of hospitalization were collected from electronic medical records.ResultsUp to April 30th 2020, 6,424 patients from 109 hospitals were included. …

medicine.medical_specialtyRespiratory distressbusiness.industryMortality rateMedical recordHydroxychloroquineRetrospective cohort studyLopinavirmedicine.diseaseInternal medicineEpidemiologymedicinebusinessDyslipidemiamedicine.drug
researchProduct

Fructose and cardiometabolic disorders: the controversy will, and must, continue

2010

The present review updates the current knowledge on the question of whether high fructose consumption is harmful or not and details new findings which further pushes this old debate. Due to large differences in its metabolic handling when compared to glucose, fructose was indeed suggested to be beneficial for the diet of diabetic patients. However its growing industrial use as a sweetener, especially in soft drinks, has focused attention on its potential harmfulness, possibly leading to dyslipidemia, obesity, insulin resistance/metabolic syndrome and even diabetes. Many new data have been generated over the last years, confirming the lipogenic effect of fructose as well as risks of vascular…

medicine.medical_specialtyReviewFructoseBiologyBioinformaticschemistry.chemical_compoundInsulin resistanceRisk FactorsInternal medicineDiabetes mellitusmedicineHumansVascular DiseasesTriglyceridesHypertriglyceridemialcsh:R5-920HypertriglyceridemiaFructoseGeneral Medicinemedicine.diseaseObesityMetabolic syndromeDietEndocrinologychemistryLiverSweetening AgentsHypertensionUric acidMetabolic syndromelcsh:Medicine (General)Uric acidDyslipidemiaClinics
researchProduct

Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System

2009

Nitric oxide (NO) produced by endothelial NO synthase (eNOS) represents an anti-atherosclerotic principle. NO bioavailability is decreased in atherosclerosis due to increased NO inactivation by reactive oxygen species and reduced NO synthesis. Various types of vascular pathophysiology are associated with oxidative stress, with NADPH oxidases as the major source of reactive oxygen species. These inactivate NO. Also, oxidative stress is likely to be the main cause for oxidation of the essential NOS cofactor, tetrahydrobiopterin (BH(4)). A lack of BH(4) leads to eNOS uncoupling (i.e., uncoupling of oxygen reduction from NO synthesis in eNOS). Based on these pathomechanisms, the therapeutic pot…

medicine.medical_specialtySepiapterinNitric Oxide Synthase Type IIImedicine.drug_classGTP cyclohydrolase INitric Oxidemedicine.disease_causeRenin inhibitorNitric oxidechemistry.chemical_compoundEnosInternal medicineDrug DiscoverymedicineAnimalsHumansHypolipidemic AgentsPharmacologybiologyArteriesTetrahydrobiopterinAtherosclerosisbiology.organism_classificationNitric oxide synthaseOxidative StressTreatment OutcomeEndocrinologychemistrybiology.proteinOxidative stressSignal Transductionmedicine.drugCurrent Pharmaceutical Design
researchProduct

One year after the ESC/EAS guidelines on cholesterol control. What's the new evidence? What's missing?

2021

The recent ESC/EAS 2019 Guidelines for the management of dyslipidaemias are centred on the causal role of low density lipoprotein (LDL), or more generally apolipoprotein B (apoB)-containing lipoproteins, in atherosclerosis as an essential principle. Despite updated goals and recommendations, that have further highlighted the importance of a powerful reduction in LDL-C levels to reduce the individual CV risk, some challenges remain to be addressed in view of future guideline elaboration. In this review, we will summarize the new evidence from clinical trials since 2019 guideline release and discuss the possible challenges for the future.

medicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BControl (management)Guidelinechemistry.chemical_compoundRisk FactorsCardiovascular DiseasePrimary preventionCardiovascular disease DyslipidemiaInternal MedicineHumansMedicineIntensive care medicineDyslipidemiasSecondary preventionPrimary preventionbiologybusiness.industryCholesterolSecondary preventionLDL-C treatmentCholesterol LDLGuidelineAtherosclerosisClinical trialCholesterolchemistryCardiovascular Diseasesbiology.proteinlipids (amino acids peptides and proteins)Risk Factors: AtherosclerosiHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessEuropean Journal of Internal Medicine
researchProduct

Obesity and cardiovascular risk: the new public health problem of worldwide proportions

2004

Obesity could be considered a new global health epidemic above all others, especially when it is characterized by central fat distribution. This is illustrated by dramatic provisional data, indicating a continuous increase in the trend of overweight and obese individuals in several countries, including the USA and countries in Europe. Several epidemiological, pathophysiological and clinical studies clearly indicate that two of the major independent risk factors for cardiovascular disease or events are being overweight, and obesity. Accordingly, weight loss and prevention of weight gain has to be considered one of the most important strategies to reduce the incidence of cardiovascular diseas…

medicine.medical_specialtySettore MED/09 - Medicina InternaCoronary DiseaseHyperlipidemiasDiseaseOverweightGlobal HealthBody Mass IndexRisk FactorsWeight lossEnvironmental healthEpidemiologyInternal MedicinemedicineGlobal healthHumansObesityHeart Failurecardiovascular risk heart failure hypertension ischemic heart disease obesitybusiness.industryPublic healthGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareObesityUnited StatesEuropeCardiovascular DiseasesHypertensionPhysical therapyAnti-Obesity Agentsmedicine.symptomCardiology and Cardiovascular MedicinebusinessBody mass indexExpert Review of Cardiovascular Therapy
researchProduct

A novel component of the metabolic syndrome: The oxidative stress

2009

The metabolic syndrome (MS) represents a cluster of cardiovascular (CV) risk factors associated to CV disease and type 2 diabetes. It is still under debate whether MS is a mere aggregation of risk factors or it represents a clinical entity with visceral obesity as underlying pathophysiological trigger. The publication of several diagnostic criteria of MS by scientific associations or experts panels reflects this uncertainty in understanding the real nature of MS. Besides the metabolic disturbances of MS, as visceral obesity, hypertriglyceridemia, low HDL cholesterol, hypertension and hyperglycemia, novel mechanisms of arterial damage have been identified. This paper reviews the evidence sho…

medicine.medical_specialtySettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Blood lipidsType 2 diabetesDiseaseBiologyBioinformaticsmedicine.disease_causeRisk FactorsInternal medicineDiabetes mellitusmedicineAnimalsHumansDyslipidemiasInflammationMetabolic SyndromeNutrition and DieteticsHypertriglyceridemiaCardiovascular riskmedicine.diseaseObesityOxidative StressEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesObesity AbdominalHypertensionMetabolic syndromeCardiology and Cardiovascular MedicineOxidative stressNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Matrix metalloproteinases in metabolic syndrome.

2011

Metabolic syndrome is commonly accompanied by an elevated cardiovascular risk with high morbidity and mortality. The alterations of the arterial vasculature begin with endothelial dysfunction and lead to micro- and macrovascular complications. The remodeling of the endothelial basal membrane, that promotes erosion and thrombosis, has a multifactorial pathogenesis that includes leukocyte activation, increased oxidative stress and also an altered matrix metalloproteinases (MMPs) expression. MMPs are endopeptidases which degrade extracellular matrix proteins, such as collagen, gelatins, fibronectin and laminin. They can be secreted by several cells within the vascular wall, but macrophages are…

medicine.medical_specialtySettore MED/09 - Medicina InternaMatrix metalloproteinaseGlobal HealthPathogenesisExtracellular matrixRisk FactorsDiabetes mellitusInternal medicineInternal MedicinemedicineHumansEndothelial dysfunctionMetabolic Syndromebiologybusiness.industryMETABOLIC SYNDROME MATRIX METALLOPROTEASES CARDIOVASCULAR RISKmedicine.diseaseMatrix MetalloproteinasesSurvival RateFibronectinOxidative StressEndocrinologyCardiovascular Diseasesbiology.proteinMorbidityMetabolic syndromebusinessDyslipidemia
researchProduct

Protein oxidation in metabolic syndrome

2013

Purpose: Oxidative stress plays a pivotal role in the pathogenesis of the metabolic syndrome and in the progression of its complications. Carbonylated proteins are a stable marker of severe oxidative stress because damage to the protein structure is irreversible and may cause an inhibition of their enzymatic activity or an increased susceptibility to proteolysis. There are few data regarding protein oxidation in metabolic syndrome, although elevated levels of carbonyl groups are often detected in subjects with obesity, diabetes mellitus, hypertension or dyslipidemia, well-known components of the metaboic syndrome. In particular, obesity, insulin resistance and diabetes mellitus are frequent…

medicine.medical_specialtySettore MED/09 - Medicina InternaProtein CarbonylationBiologyProtein oxidationmedicine.disease_causeProtein CarbonylationInsulin resistanceDiabetes mellitusInternal medicinemedicineAnimalsHumansMetabolic SyndromeInterleukin-6Tumor Necrosis Factor-alphaGeneral Medicinemedicine.diseaseOxidative Stressprotein oxidation metabolic syndromeEndocrinologyResistinMetabolic syndromeInsulin ResistanceDyslipidemiaOxidative stress
researchProduct

Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis.

2011

Objective To quantify the magnitude and pattern of low-density lipoprotein (LDL) cholesterol and nonhigh-density lipoprotein (HDL) cholesterol levels in women with polycystic ovary syndrome (PCOS) versus control women. Design Systematic review and meta-analysis of lipid levels in published cross-sectional studies worldwide where PCOS women and controls were examined and sampled. Main Outcome Measure(s) Differences in plasma lipids (including triglycerides, HDL-cholesterol, LDL-cholesterol, and nonHDL-cholesterol) in PCOS versus control subjects were calculated. Comparisons were made with and without body mass index (BMI) matching. Result(s) Triglyceride levels were 26 mg/dL (95% confidence …

medicine.medical_specialtySettore MED/13 - EndocrinologiaBody Mass Indexchemistry.chemical_compoundRisk FactorsMedicineHumansDyslipidemiasGynecologyTriglyceridebusiness.industryCholesterolHyperandrogenismnutritional and metabolic diseasesObstetrics and Gynecologymedicine.diseasePolycystic ovaryLipidsConfidence intervalReproductive MedicinechemistryPolycystic Ovary Syndrome dyslipidemia cardiovascular risklipids (amino acids peptides and proteins)FemalebusinessHyperandrogenismBody mass indexDyslipidemiaLipoproteinPolycystic Ovary SyndromeFertility and sterility
researchProduct